Clinical Trial Update: Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy plus bevacizumab for HER2-negative breast cancer in stage II/III; the study has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stage Iiia Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: University of Nebraska | Conditions: HER2-negative Breast Cancer, Stage II Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-12-12